Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Timothy M Nywening, Andrea Wang-Gillam, Dominic E Sanford, Brian A Belt, Roheena Z Panni, Brian M Cusworth, Adetunji T Toriola, Rebecca K Nieman, Lori A Worley, Motoyo Yano, Kathryn J Fowler, A Craig Lockhart, Rama Suresh, Benjamin R Tan, Kian-Huat Lim, Ryan C Fields, Steven M Strasberg, William G Hawkins, David G DeNardo, S Peter Goedegebuure, David C Linehan
The Lancet. Oncology 2017;17(5):651-62